1. Home
  2. NFJ vs MNKD Comparison

NFJ vs MNKD Comparison

Compare NFJ & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest

NFJ

Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest

N/A

Current Price

$14.23

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$3.73

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NFJ
MNKD
Founded
2005
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2003
2004

Fundamental Metrics

Financial Performance
Metric
NFJ
MNKD
Price
$14.23
$3.73
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.08
AVG Volume (30 Days)
332.8K
★ 3.3M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 9.01%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $348,966,000.00
Revenue This Year
N/A
$26.63
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 22.23
52 Week Low
$12.25
$2.23
52 Week High
$15.75
$6.51

Technical Indicators

Market Signals
Indicator
NFJ
MNKD
Relative Strength Index (RSI) 33.31 61.07
Support Level $14.14 $3.24
Resistance Level $15.20 $4.28
Average True Range (ATR) 0.20 0.15
MACD -0.03 0.08
Stochastic Oscillator 10.46 95.65

Price Performance

Historical Comparison
NFJ
MNKD

About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest

Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: